Six firms currently cover Recursion Pharmaceuticals, issuing one sell, three hold and two buy recommendations, resulting in a consensus rating of Hold. Over the past year these brokers have placed their average twelve-month price target at $9.40. On December 17th, three major banks independently set or raised their targets to $11.00 and upgraded sentiment, while in October one ratings agency reaffirmed its sell (D–) view.

During the past quarter, two senior executives sold a combined 241,383 shares for total proceeds of roughly $1.05 million. Director Blake Borgeson generated $959,200 by disposing of 220,000 shares on January 6th, reducing his stake by 3.20% to 6.65 million shares. CFO Ben R. Taylor sold 21,383 shares on December 29th for $89,380.94, trimming his position by 2.73% to 761,550 shares. Overall insider sales in the last ninety days totaled 585,786 shares valued at $2.56 million.

Major institutional investors have significantly adjusted their holdings. In Q1, UBS Asset Management Americas boosted its stake by 183.7%, adding 4.15 million shares to hold 6.41 million shares worth roughly $33.9 million. Norges Bank initiated a $16.0 million position in Q2, while Bank Pictet & Cie Europe added $7.95 million in Q3. Stratos Wealth Partners increased its position by 724.3% in Q2 to 98,704 shares, and Ethic Inc. opened a position valued at $107,000. Hedge funds and other institutions now own 89.06% of shares outstanding.

In Q3, Recursion reported revenue of $5.18 million, down 80.1% year-over-year and missing analysts’ $19.36 million estimate, while delivering an EPS loss of $0.36, slightly above the consensus of $0.38. The company ended the period with a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60. Despite a negative return on equity of 72.7% and a net margin of –1,637.8%, management projects a full-year loss per share of approximately 1.57.